Hans Holger Fischer

Publication Activity (10 Years)

Years Active: 2022-2022
Publications (10 Years): 2

This page only lists publications with an associated author ORCID identifier.

Publications

Monika Gräser, Oleg Gluz, Claudia Biehl, Daniel Ulbrich-Gebauer, Matthias Christgen, Jenci Palatty, Sherko Kuemmel, Eva-Maria Grischke, Doris Augustin, Michael Braun, Jochem Potenberg, Rachel Wuerstlein, Katja Krauss, Claudia Schumacher, Helmut Forstbauer, Toralf Reimer, Andrea Stefek, Hans Holger Fischer, Enrico Pelz, Christine Zu Eulenburg, Ronald Ernest Kates, Hua Ni, Cornelia Kolberg-Liedtke, Friedrich Feuerhake, Hans Heinrich Kreipe, Ulrike Nitz, Nadia Harbeck
Impact of RNA signatures on pCR and survival after 12-week neoadjuvant pertuzumab plus trastuzumab with or without paclitaxel in the WSG-ADAPT-HER2+/HR- trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Ulrike A Nitz, Oleg Gluz, Sherko Kuemmel, Matthias Christgen, Michael Braun, Bahriye Aktaş, Kerstin Lüdtke-Heckenkamp, Helmut Forstbauer, Eva-Maria Grischke, Claudia Schumacher, Maren Darsow, Katja Krauss, Benno Nuding, Marc Thill, Jochem Potenberg, Christoph Uleer, Mathias Warm, Hans Holger Fischer, Wolfram Malter, Michael Hauptmann, Ronald E Kates, Monika Gräser, Rachel Würstlein, Steven Shak, Frederick L Baehner, Hans H Kreipe, Nadia Harbeck
Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (23) (2022)